Fallopian Tube Cancer Pipeline Outlook Report 2025: Key 70+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's, "Fallopian Tube Cancer Pipeline Insight 2025" report provides comprehensive insights about 70+ Fallopian tube cancer companies and 70+ pipeline drugs in Fallopian Tube Cancer pipeline landscape. It covers the Fallopian Tube Cancer pipeline drug profiles, including clinical and nonclinical stage products. Fallopian tube cancer pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Fallopian Tube Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Fallopian Tube Cancer Pipeline Report

* In August 2025, Corcept Therapeutics announced a Phase 2, single-arm, open-label study to evaluate efficacy and safety of intermittent dosing of relacorilant in combination with nab-paclitaxel and bevacizumab in patients with ovarian cancer.
* In August 2025, AbbVie conducted a study is to assess the safety and efficacy of for Mirvetuximab Soravtansine in participants with platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer (platinum-resistant ovarian cancer) (PROC) whose tumors express a high level of folate receptor alpha (FR).
* In August 2025, Imunon conducted a phase 3 study evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer.
* In August 2025, Daiichi Sankyo conducted a study will focus on R-DXd in participants with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer. R-DXd is an antibody-drug conjugate that specifically binds to CDH6, which is overexpressed in tumor cells. The Phase 2 dose-optimization part of the study (Part A) intends to define the recommended dose based on safety and efficacy, while the Phase 3 (Part B) part of the study will compare R-DXd with Investigator's choice of chemotherapy and further evaluate efficacy.
* DelveInsight's Fallopian Tube Cancer pipeline report depicts a robust space with 70+ active players working to develop 70+ pipeline therapies for Fallopian Tube Cancer treatment.
* The leading Fallopian Tube Cancer Companies such as ImmunoGen, Janssen Research & Development, OncXerna Therapeutics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma/Celgene, Astex Pharmaceuticals, Lee's Pharmaceutical, Genmab/Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Eli Lilly and Company, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Compugen, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, and Tmunity Therapeutics and others.
* Promising Fallopian Tube Cancer Pipeline Therapies such as Bevacizumab, Trabectedin, Dexamethasone, epothilone b, Avastin, Docetaxel, Paclitaxel, BIBF 1120, Mirvetuximab soravtansine, Carboplatin, Sargramostim and others.

Learn how leading Fallopian Tube Cancer Companies are positioning themselves for success in the evolving pharmaceutical market-access the full report today!" @ Fallopian Tube Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Fallopian Tube Cancer Emerging Drugs Profile

* Mirvetuximab Soravtansine: ImmunoGen

Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor (FR). It consists of the humanized anti-FR mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4. It is currently in phase III stage of development and is being developed by Immunogen.

* Tisotumab vedotin: Genmab/Seagen

Tisotumab vedotin is designed to target tissue factor (TF) using our proprietary antibody-drug conjugate (ADC) technology. TF is highly expressed on many solid tumors, including ovarian, prostate, bladder, esophageal, endometrial, and lung tumors. Tisotumab vedotin is being developed in collaboration with Genmab. It is composed of Genmab's human monoclonal antibody (mAb) that binds to TF and Seagen's ADC technology that utilizes a cleavable linker and the cytotoxic drug monomethyl auristatin E (MMAE). It is currently in phase III stage of development.

* Pembrolizumab: Merck & Co.

Keytruda (pembrolizumab) is a drug developed by Merck used in cancer therapy. It is a monoclonal antibody, a protein that binds to specific ligands, which increases the ability of the immune system to help detect and fight tumor cells. Keytruda has already been approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancers including melanoma, non-small cell lung cancer, recurrent or metastatic head and neck cancer, classical Hodgkin lymphoma, and urothelial carcinoma. The drug is still under investigation for the treatment of ovarian cancer, Fallopian tube cancer and several other potential disease.

The Fallopian Tube Cancer Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Fallopian Tube Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Fallopian Tube Cancer Treatment.
* Fallopian Tube Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Fallopian Tube Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Fallopian Tube Cancer market.

From early-stage research to late-phase Fallopian Tube Cancer Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed-download now! @ Fallopian Tube Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Fallopian Tube Cancer Companies

ImmunoGen, Janssen Research & Development, OncXerna Therapeutics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma/Celgene, Astex Pharmaceuticals, Lee's Pharmaceutical, Genmab/Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Eli Lilly and Company, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Compugen, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, and Tmunity Therapeutics and others.

Fallopian Tube Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Fallopian Tube Cancer Products have been categorized under various ROAs such as

* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Oral
* Parenteral
* Subcutaneous
* Topical
* Molecule Type

Fallopian Tube Cancer Products have been categorized under various Molecule types such as

* Vaccines
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Product Type

Stay updated with the latest Fallopian Tube Cancer Pipeline Insights-download our report for a deep dive into the next generation of therapeutics! @ Fallopian Tube Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Fallopian Tube Cancer Pipeline Report

* Coverage- Global
* Fallopian Tube Cancer Companies- ImmunoGen, Janssen Research & Development, OncXerna Therapeutics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma/Celgene, Astex Pharmaceuticals, Lee's Pharmaceutical, Genmab/Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Eli Lilly and Company, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Compugen, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, and Tmunity Therapeutics and others.
* Fallopian Tube Cancer Pipeline Therapies- Bevacizumab, Trabectedin, Dexamethasone, epothilone b, Avastin, Docetaxel, Paclitaxel, BIBF 1120, Mirvetuximab soravtansine, Carboplatin, Sargramostim and others.
* Fallopian Tube Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Fallopian Tube Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Fallopian Tube Cancer Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ Fallopian Tube Cancer Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Fallopian Tube Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Fallopian Tube Cancer - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Fallopian Tube Cancer Collaboration Deals
* Late Stage Products (Phase III)
* Mirvetuximab Soravtansine: ImmunoGen
* Mid Stage Products (Phase II)
* Gimatecan: Lee's Pharmaceuticals
* Early stage products (Phase I)
* TG4050: Transgene
* Inactive Products
* Fallopian Tube Cancer Key Companies
* Fallopian Tube Cancer Key Products
* Fallopian Tube Cancer- Unmet Needs
* Fallopian Tube Cancer- Market Drivers and Barriers
* Fallopian Tube Cancer- Future Perspectives and Conclusion
* Fallopian Tube Cancer Analyst Views
* Fallopian Tube Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=fallopian-tube-cancer-pipeline-outlook-report-2025-key-70-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/fallopian-tube-cancer-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.